课题基金 / 基金详情

PROMISS - Prostate Modeling to Identify Surveillance Strategies

PROMISS - Prostate Modeling to Identify Surveillance Strategies
PROMISS - 前列腺建模以确定监测策略
批准号:
8656071
负责人:
RUTH D ETZIONI
金额:
$63.78万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-30 至 2018-08-31

项目摘要

项目成果

RUTH D ETZIONI的其他基金

相似基金

相关文献

中文摘要
翻译
7.项目总结 这项应用解决了前列腺癌管理中最关键的难题,也就是最复杂的- 美国男性患皮肤癌后罹患癌症。年,PSA筛查在美国的广泛采用 20世纪90年代在这个国家造成了低风险前列腺癌的流行。绝大多数低风险病例 不会死于他们的疾病,但他们继续寻求治疗。主动监视(AS)已经- 被一个权威专家小组认为是管理低风险前列腺癌的可行选择,但没有证据- 对于如何实现它,存在基于标准的。在强直性脊柱炎中,病例受到密切监测,如果有 任何疾病进展的证据。几项AS研究正在进行中,但它们构成了一个松散的集合 不同的方法及其结果不能轻易地比较或综合。的首要目标是 这一应用是为了确定一种最佳的方法,以满足给定的患者特征和偏好。记录- 认识到许多潜在的AS治疗方法在临床试验中是无法比较的,我们将利用我们的 对前列腺癌的进展和预后进行建模以预测短期和长期的丰富经验 应聘者的结果作为战略。该模型将建立在对5种疾病进展的荟萃分析基础上 作为最高质量和最大规模的研究。这将由一种独立的疾病模型来补充 在缺乏治疗的情况下进展,以适应现有的基于人群的前列腺癌模型 自然历史到AS环境。我们将叠加候选人作为战略,并将进展与 基于已发表的复发、病态疾病研究,治疗事件与治疗后存活率和生活质量有关 TY,以及初级处理后的公用事业。由此产生的模型将预测一系列结果,包括 无治疗间隔、疾病特定生存期和质量调整后的生命年。结果将是打包的- 在一个界面中,患者可以使用该界面来比较根据他们的个人定制的不同策略的结果 AL的特点和偏好。我们的具体目标是:目标1:建立前列腺癌进展模型 作为AS候选对象的低风险前列腺癌患者缺乏治疗。作为这一目标的一部分,我们 将对正在进行的AS研究进行第一次荟萃分析。目标2:项目并比较短期和长期 不同AS方案的结果,使用目标1中开发的模型以及生存和生活质量 来自先前对AS和局部疾病治疗方法的研究的信息。目标3:开发、测试和 发布使用这些模型的界面,以帮助患者基于他们的 诊断时的临床和病理特征、健康状况和个人喜好。 这项应用将推进AS的证据基础,并将是第一次,因为战略已经制定。 在一个连贯的医疗决策框架内使用相同的指标进行了削减。这场危机的主要影响 工作在于它有可能为患者的决策提供信息,从而使AS变得更容易被接受和改进 在美国,每年被诊断为低风险前列腺癌的许多男性的质量调整后的预期寿命。
英文摘要
7. PROJECT SUMMARY This application addresses the most critical conundrum in the management of prostate cancer, the most com- mon cancer after skin cancer in US men. The widespread adoption of PSA screening in the US during the 1990s has created an epidemic of low-risk prostate cancer in this country. The vast majority of low-risk cases will not die of their disease yet they continue to seek curative treatment. Active surveillance (AS) has been en- dorsed by an authoritative panel as a viable option for managing low-risk prostate cancer, but no evidence- based standard exists for how to implement it. In AS, cases are closely monitored and intent to treat if there is any evidence of disease progression. Several AS studies are ongoing but they constitute a loose collection of different approaches and their results cannot be readily compared or integrated. The overarching objective of this application is to determine an optimal approach to AS given patient characteristics and preferences. Rec- ognizing that the many potential approaches to AS cannot be compared in clinical trials, we will draw on our extensive experience modeling prostate cancer progression and prognosis to project the short- and long-term outcomes of candidate AS strategies. The model will build on a meta-analysis of disease progression across 5 of the highest quality and largest AS studies. This will be complemented by an independent model of disease progression in the absence of treatment that will adapt an existing, population-based model of prostate cancer natural history to the AS setting. We will superimpose candidate AS strategies and link the progression and treatment events with post-treatment survival and quality of life based on published studies of relapse, morbidi- ty, and utilities following primary treatment. The resulting model will project a range of outcomes, including the treatment-free interval, disease-specific survival, and quality-adjusted life years. The outcomes will be pack- aged in an interface that patients can use to compare outcomes of different strategies tailored to their individu- al characteristics and preferences. Our Specific Aims are: Aim 1: Model prostate cancer progression in the absence of treatment among low-risk prostate cancer cases who are candidates for AS. As part of this aim we will conduct the first meta-analysis of ongoing AS studies. Aim 2: Project and compare short- and long-term outcomes on various AS protocols, using the models developed in Aim 1 along with survival and quality of life information from prior studies of AS and curative treatments for localized disease. Aim 3: Develop, test and release an interface using these models to help patients identify a personalized AS approach based on their clinical and pathologic characteristics at the time of diagnosis, their health status, and personal preferences. This application will advance the evidence base for AS and will be the first time AS strategies have been com- pared using the same metrics within a coherent medical decision-making framework. The main impact of the work lies in its potential to inform patient decision-making so that AS becomes more accepted and improves quality-adjusted life expectancy for the many men diagnosed low-risk prostate cancer each year in the US.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modeling Precision Interventions for Prostate Cancer Control
  • 批准号:
    10683180
  • 项目类别:
  • 资助金额:
    $123.52万
  • 财政年份:
    2020
  • 负责人:
    RUTH D ETZIONI
  • 依托单位:
Modeling Precision Interventions for Prostate Cancer Control
  • 批准号:
    10461832
  • 项目类别:
  • 资助金额:
    $127.05万
  • 财政年份:
    2020
  • 负责人:
    RUTH D ETZIONI
  • 依托单位:
Modeling Precision Interventions for Prostate Cancer Control
  • 批准号:
    10601453
  • 项目类别:
  • 资助金额:
    $65.41万
  • 财政年份:
    2020
  • 负责人:
    RUTH D ETZIONI
  • 依托单位:
Modeling Precision Interventions for Prostate Cancer Control
海外基金